GE HealthCare Technologies Inc. · NASDAQ:GEHC

GE HealthCare Technologies — Technical Presentation (May 2020)

80 slides from GE HealthCare Technologies's technical presentation, May 3, 2020

  1. Slide 1: Exclusive property of GE Healthcare

    Exclusive property of GE Healthcare - No part of the following content made available by GE Healthcare may be copied, photocopied, reproduced, translated or reduced to any electronic medium or machine-readable form, in whole or in part, without prior written consent of the owner, GE Healthcare. Any

  2. Slide 2: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 2

  3. Slide 3: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 3

  4. Slide 4: Easter Friday 10th April 15:00

    Easter Friday 10th April 15:00 https://coronavirus.jhu.edu/map.html Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 4

  5. Slide 5: 30th April 20:00

    30th April 20:00 https://coronavirus.jhu.edu/map.html Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 5

  6. Slide 6: Cases per day and deaths per day accumulated over 7 days

    Cases per day accumulated over 7 days Deaths per day accumulated over 7 days Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 6

  7. Slide 7: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 7

  8. Slide 8: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 8

  9. Slide 9: www.intensivregister.de

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 9 www.intensivregister.de

  10. Slide 10: Ventilated Covid-19 patients, free ICU beds, Covid-19 patients

    Ventilated Covid-19 patients free ICU beds Covid-19 Patients Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 10 www.intensivregister.de

  11. Slide 11: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 11

  12. Slide 12: Easter Friday 10th April 15:00

    Easter Friday 10th April 15:00 normal ICU beds max. ICU beds occupied ICU beds free ECMO beds Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 12

  13. Slide 13: 30th April 20:00

    30th April 20:00 normal ICU beds max. ICU beds occupied ICU beds free ECMO beds Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 13

  14. Slide 14: Hoping for the best, prepared for the worst

    Hoping for the best, prepared for the worst, and unsurprised by anything in between. Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 14

  15. Slide 15: Individualized approach for COVID-19 pneumonia

    Individualized approach for COVID-19 pneumonia What is best? Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 15

  16. Slide 16: Best practice in mechanical ventilation?

    Best practice in mechanical ventilation? • VT: 6 ml/kg pbw for all patients and PAW < 28 • NEJM 2000 • PEEP: ARDS network table based on Oxygenation • NEJM 2000 or NEJM 2004 • High PEEP: for severe ARDS • JAMA 2010 • Prone: for severe ARDS • NEJM 2013 • NMB: for severe ARDS or not? • NEJM 2010/JAMA

  17. Slide 17: Co-published article in Critical Care Medicine

    This article is being co-published in Critical Care Medicine (DOI: 10.1097/CCM.0000000000004363) and Intensive Care Medicine (DOI: 10.1007/s00134-020-06022-5). Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 17

  18. Slide 18: Co-published article in Critical Care Medicine

    This article is being co-published in Critical Care Medicine (DOI: 10.1097/CCM.0000000000004363) and Intensive Care Medicine (DOI: 10.1007/s00134-020-06022-5). Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 18

  19. Slide 19: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 19

  20. Slide 20: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 20

  21. Slide 21: n = 16 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is

    n = 16 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 21

  22. Slide 22: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 22

  23. Slide 23: was

    was Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 23

  24. Slide 24: Gattinoni's dichotomous model

    Gattinoni’s dichotomous model Type L Type H • Low elastane • High elastane • Low VA/Q mismatch • High R-L shunt • Low lung weight • High lung weight • Low recruit ability • High recruitability Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 24

  25. Slide 25: Lung damage progression (SARS-CoV-2 + P-SILI)

    Lung damage progression (SARS CoV 2 + P-SILI) O2 NIV early late HFNC Intubation Intubation Type L Type H • Low elastane • High elastane • Low VA/Q mismatch • High R-L shunt • Low lung weight • High lung weight • Low recruit ability • High recruitability Exclusive property of GE Healthcare. Any unaut

  26. Slide 26: We are treating hypoxia and respiratory distress

    Individualized approach for COVID-19 associated ARDS (CARDS) We are not treating ARDS or CARDS we are treating Hypoxia and respiratory distress Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 26

  27. Slide 27: Hypoxia prevented by hyperventilation

    Hypoxia prevented by hyperventilation Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 27

  28. Slide 28: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 28

  29. Slide 29: Patient self-inflicted lung injury (P-SILI)

    Excessive effort to breathe due to high respiratory drive may lead to patient self-inflicted lung injury (P-SILI), even in the absence of mechanical ventilation. Give O2 until hyperventilation is decreasing independent of SpO2 Exclusive property of GE Healthcare. Any unauthorized reproduction or use

  30. Slide 30: NIV in Covid-19

    NIV in Covid-19 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 30

  31. Slide 31: Intubation in Covid-19: harm more than benefit?

    Intubation in Covid-19: harm more than benefit? Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 31

  32. Slide 32: Personal protection equipment in patient care

    personal protection equipment (PPE) are essential in the care of patients Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 32

  33. Slide 33: Personal protection equipment in patient care

    personal protection equipment (PPE) are essential in the care of patients Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 33

  34. Slide 34: Stepwise oxygen, NIV and intubation approach

    paO2 < 60, Hyperventilation O2 ; (HFNC) ✅ check at least every 2 hours SPO2 < 92%?, CO2 not NIV: PEEP 10, PS 8 - 15 ✅ check at least every 2 hours SPO2 < 92%?, Respiratory distress? Intubation: Start PEEP 12 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohib

  35. Slide 35: L-Type Covid-19

    L- Type Covid-19 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 35

  36. Slide 36: JAMA 2018;320(18):1872-1880

    JAMA. 2018;320(18):1872-1880 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 36

  37. Slide 37: JAMA 2018;320(18):1872-1880

    JAMA. 2018;320(18):1872-1880 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 37

  38. Slide 38: Driving pressure = PIP - PEEP

    ∆ P = PIP - PEEP JAMA. 2018;320(18):1872-1880 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  39. Slide 39: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 39

  40. Slide 40: H-Type Covid-19

    H- Type Covid-19 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 40

  41. Slide 41: One size does not fit all!

    one size does not fits all! Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 41

  42. Slide 42: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 42

  43. Slide 43: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 43

  44. Slide 44: Curr Opin Crit Care 2020;26(1):59-65

    Curr Opin Crit Care. 2020 Feb;26(1):59-65 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 44

  45. Slide 45: Curr Opin Crit Care 2020, 26:26-34

    Curr Opin Crit Care 2020, 26:26 – 34 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 45

  46. Slide 46: Ventilatory support in Covid-19

    Ventilatory support in Covid-19 1. Covid-19 pneumonia is a heterogeneous picture 2. There is no one-size-fits-all approach 3. P-SILI is one key parameter 4. Oxygenation or P/F ratio is not helpful to titrate PEEP • ARDSnet table is useless 5. Do not „super optimize“ blood gases • pH 7.25 6. You have

  47. Slide 47: A very pragmatic approach

    A very pragmatic approach ∆P 15 PEEP Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 47

  48. Slide 48: Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

    Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited 48

  49. Slide 49: COVID-19: ECMO considerations

    COVID-19: ECMO considerations Philipp M. Lepper Dept. of Internal Medicine V ECLS Center Saar University Hospital of Saarland

  50. Slide 50: UKS COVID-19 ICU

    UKS COVID-19 ICU • 24 bed ICU with dedicated ECMO-service (including mobile ECMO team) • ICU solely for COVID + ICU patients • Set up of airlock chamber and strict isolation of all COVID + • PPE with overall, FFP3 mask, safety goggles + visor, double gloves • First COVID + patient arrived March, 14t

  51. Slide 51: UKS COVID-19 ICU Part (16 bed unit)

    UKS COVID-19 ICU Part 1 (16 bed unit) C Floor Airlock chamber B Floor Bed Door Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  52. Slide 52: COVID-19 Infection control

    COVID-19 Infection control • Education and re-education on PPE • Strong emphasis on basic hygiene measures • No visitors allowed on ICU (exemtion possible for relatives of dying patients) • Enhanced surveillance for infection in HCW • Stress and burn-out prophylaxis ➢ 4-shift model to reduce duratio

  53. Slide 53: COVID-19: transfer of French patients

    COVID-19: transfer of french patients UKS ECMO Team Tour de France Deployment of UKS ECMO team with 2 helicopters to retrieve french COVID patients: in total 7 transferred Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  54. Slide 54: COVID-19: Case I

    COVID-19; Case I K., J.: 60 years old; otherwise healthy, no known previous conditions • Intubation 26.03. COVID + 15.03. • Prone position 27.03. – 31.03. Klebsiella aerogenes 3MRGN 10.04. • Tracheotomy 31.03. • vvECMO 03.04. (OI 76) • awake ECMO since 29.04. (2 L BF, 7 L sweep-flow); to date 30 day

  55. Slide 55: COVID-19: Case II

    COVID-19: Case II A., M.: 69 years old; art. Hypertension, Diabetes mellitus, Obesity • Intubation 16.03. COVID + 11.03. • Prone position 17.03. – 23.03. • Extubation 25.03. • NIV 25.03. – 01.04. • Reintubation 01.04. • Tracheotomy 02.04. • vvECMO 01.04. – 23.04. (OI 50) March 31st May 2nd Exclusive

  56. Slide 56: COVID-19: Case III

    COVID-19: Case III G., J.-L.: 60 years old; art. Hypertension, Obesity • Intubation 19.03. COVID + 12.03. • Prone position n.d. • Tracheotomy 28.03. • vvECMO 28.03. (OI 77) – 02.05. March 25th May 2nd Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  57. Slide 57: COVID-19: Case III

    COVID-19: Case III March 19th G., J.-L.: 60 years old; art. Hypertension, Obesity Lab values 23.03. 30.03. 02.05. Leukocytes 15.8 24.0 17.8 G/L Lymphocytes 4 4 3 % CRP 330 383 20.5 mg/L IL-6 247.6 12,504* 19.6 pg/mL Ferritin n.a. 1005 2176 ng/mL D-Dimers 2.26 25.21 >33.0 mg/L PCT 9.31 1.57 0.29 ng/m

  58. Slide 58: ECMO and COVID-19: a bad idea?

    ECMO and COVID-19: a bad idea ? What might be causes for bad outcome ? Henry BM et al. J Crit Care 2020 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  59. Slide 59: EOLIA: DSMB safety analysis

    EOLIA: DSMB – safety analysis Z Stop for efficiency Stop for futility Stop for harm • recruitment stopped • 4th planned interim analysis (each after 60 included patients) ➢ 240 patients ➢ till April 2017 • lower boundary of “stopping-rule triangle” crossed ➢ difference between groups unlikely Combes

  60. Slide 60: EOLIA: comparison between groups

    EOLIA: comparison between groups ECMO works with regard to certain technical parameters Combes A at al. NEJM 2018 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  61. Slide 61: EOLIA: Results per protocol

    EOLIA: Results per protocol Death: RR 0.76 (95% CI 0.55 – 1.04; P = 0.07) 35% 46% Combes A at al. NEJM 2018 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  62. Slide 62: COVID-19: alveolar gas equation

    COVID-19: alveolar gas equation PAO2 = (FiO2 x [Patm – PH2O]) – (paCO2/R) We may suppose that R = 0.80; alveolar-arterial O2 difference: PAO2 = (FiO2 x [Patm – PH2O]) – 24/0.8 PAO2 = (0.21 x [760 – 47]) – 30 PAO2 = (0.21 x 713) – 30 PAO2 = 120 mmHg A-a difference = 120 - 96 The alveolar-arterial O2

  63. Slide 63: COVID-19: V/Q inequality

    COVID-19: V/Q inequality • Ventilation-perfusion inequality must cause hypoxemia Normal Alveolar unit V/Q inequality 50 VO2 ↓ VCO2 ↓ CO2 mmHg pO2 ↓ pCO2 ↑ 14.6 mL/dL O2 cont. Fall in pO2 rise in pCO2 19.5 mL/dL VO2 + VCO2 normal 20.0 mL/dL pO2 ↓↓ pCO2 ↑↑ 60 80 100 120 140 Increased ventilation pO2 m

  64. Slide 64: COVID-19: V/Q inequality

    COVID-19: V/Q inequality FiO2 100% pO2 59 mmHg 1. Severe V/Q inequality; pCO2 57 mmHg 2. Preserved compliance PEEP 10 mbar 3. Increased dead space P insp 26 mbar 4. Impaired HPV (see below) TV 880 mL • DO2 relatively preserved • pH not (yet) an issue • scvO2 55% → Inotrope ? • Hemodynamics ➢ sPAP 32

  65. Slide 65: COVID-19 (and ECMO): the UKS experience

    COVID-19 (and ECMO): the UKS experience Supine *Prone position and higher PEEP • may work or may not work • both are meant to alter V/Q Prone Keep your standards • Things work best if you do them as always Cannulation should follow patient needs • Patients will mainly need vvECMO • Some might need v

  66. Slide 66: Prone Position in ARDS

    Prone Position in ARDS 474 patients randomized; prone position for ~16 h (up to 4 x) Kaplan-Meier Estimates 90 d survival [82% recieved NMBA; 40% recieved steroids] Guerin C et al. for the PROSEVA Study Group; N Engl J Med 2013 Exclusive property of GE Healthcare. Any unauthorized reproduction or us

  67. Slide 67: Reminder: venovenous ECMO

    Reminder: venovenous ECMO ECMO blood flow ~ 60% of CO to achieve SaO2 ≥ 90%  high ECMO flow in hyperdynamic states Schmidt M et al. (2013) ICM 39:838 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  68. Slide 68: COVID-19 and ECMO: what is different?

    COVID-19 and ECMO: what is different ? • Sedation o Patients might need more sedatives than we are used to o Consider also volatile anaesthetics o Fever and awake states increase CO2 production o Consider NMBA and aggressive temperature treatment • Is it still COVID-19 or bacterial or fungal superin

  69. Slide 69: NMBA in early ARDS - ROSE

    NMBA in early ARDS - ROSE 1006 randomized patients; Cisatracurium for 48 h within the first 48 h after ARDS onset Kaplan-Meier Estimates 90 d survival The National Heart, Lung, and Blood Institute PETAL Clinical Trials Network; N Engl J Med 2019 Exclusive property of GE Healthcare. Any unauthorized

  70. Slide 70: COVID-19 and ECMO: what is different?

    COVID-19 and ECMO: what is different ? • Coagulation o COVID-19 is disturbing coagulation o DIC-like phenomena likely o Anticoagulation with Heparin (PTT 45 – 55 s) o high rate of positive HIT ELISAs; • Critical evaluation of concepts o no bridge to nowhere o consider palliative care for patients th

  71. Slide 71: COVID-19: Case III

    COVID-19: Case III G., J.-L.: 60 years old; art. Hypertension, Obesity Lab values 23.03. 30.03. 02.05. units Leukocytes 15.8 24.0 17.8 G/L Lymphocytes 4 4 3 % CRP 330 383 20.5 mg/L IL-6 247.6 12,504* 19.6 pg/mL Ferritin n.a. 1005 2176 ng/mL D-Dimers 2.26 25.21 >33.0 mg/L PCT 9.31 1.57 0.29 ng/mL Fib

  72. Slide 72: Ventilation on ECMO – objectives

    Ventilation on ECMO – objectives Objectives Means Allow „lung rest“ or „ultraprotective“ ventilation Low tidals < 4 mL/kg PBW Accept higher tidals Limit Peak pressure 20 – 25 cmH2O „alveolar strain“ Limit respiratory rate Limit Maintain PEEP ≥ 8 cmH2O „atelectrauma“ Reduce SILI Acute respiratory fai

  73. Slide 73: Mechanical ventilation during ECMO

    Mechanical ventilation during ECMO complete lung rest Apnoeic ventilation + ECMO (ECCO2R) ? Johannes A et al. 2014 Pesenti A et al. 2018 Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  74. Slide 74: Mechanical ventilation during ECMO

    Mechanical ventilation during ECMO driving pressure …in ARDS Lachmann ICM 1992: “Maintain optimal gas exchange at the smallest possible pressure amplitude” Decreases in ΔP owing to changes in ventilator settings were strongly associated with increased survival. Survival benefit if P < 15 cmH2O Amat

  75. Slide 75: The concept of driving pressure

    The concept of driving pressure driving pressure … during ECMO Design: individual patient data metaanalysis (9 studies, n=545) Results: ▪ driving pressure is the only parameter independently associated with the primary endpoint (in-hospital mortality) ▪ High PEEP is not associated with increased sur

  76. Slide 76: Mechanical ventilation during ECMO

    Mechanical ventilation during ECMO Source Recommendations for Ventilator Settings for MV on ECMO ELSO guidelines ▪ decelerate flow ▪ modest PEEP ▪ low inflation pressure ▪ respiratory rate 4 - 5 European Network of ▪ PEEP ≥ 10 Mechanical Ventilation ▪ plateau pressure ≤ 20 - 25 ▪ respiratory rate 6

  77. Slide 77: ECMO and COVID-19

    ECMO and COVID-19 Recommendations….easily achivable during ECMO (not COVID-19 specific) • Reduce respiratory rate to < 12/min • Reduce patients breathing efforts • Increase Tinsp to increase mean airway pressure . • Reduce FiO2 to 0.6 or less; maintain SpO2 > 88% (DO2) • Play with PEEP and monitor f

  78. Slide 78: Conclusion

    Conclusion • ECMO might be a very good idea in COVID-19 • As always, ECMO can facilitate an „ultraprotective“ ventilation in patients with severe ARDS – especially by reducing the need for ventilation • The advantage of „facilitated ventilation“ must be protected against adverse effects ECMO might h

  79. Slide 79: Thank you for your attention

    Thank you for your attention philipp.lepper@uks.eu Exclusive property of GE Healthcare. Any unauthorized reproduction or use is strictly prohibited

  80. Slide 80: Educational purposes disclaimer

    ©2020 General Electric Company. All rights reserved. This material is intended for educational purposes only. This material does not establish specifications, operating procedures or any maintenance methods for any of the product(s) referenced. Always refer to the official written materials (labelin

GE Healthcare — Technical Presentation (May 2020) on 6ix